2023-09-012024-08-312024-08-31false08208059PHARMHE (UK) LTD2025-05-27falseiso4217:GBPxbrli:pure082080592023-09-01082080592024-08-31082080592023-09-012024-08-31082080592022-09-01082080592023-08-31082080592022-09-012023-08-3108208059bus:SmallEntities2023-09-012024-08-3108208059bus:AuditExempt-NoAccountantsReport2023-09-012024-08-3108208059bus:AbridgedAccounts2023-09-012024-08-3108208059bus:PrivateLimitedCompanyLtd2023-09-012024-08-3108208059core:WithinOneYear2024-08-3108208059core:AfterOneYear2024-08-3108208059core:WithinOneYear2023-08-3108208059core:AfterOneYear2023-08-3108208059core:ShareCapital2024-08-3108208059core:SharePremium2024-08-3108208059core:RevaluationReserve2024-08-3108208059core:OtherReservesSubtotal2024-08-3108208059core:RetainedEarningsAccumulatedLosses2024-08-3108208059core:ShareCapital2023-08-3108208059core:SharePremium2023-08-3108208059core:RevaluationReserve2023-08-3108208059core:OtherReservesSubtotal2023-08-3108208059core:RetainedEarningsAccumulatedLosses2023-08-3108208059core:LandBuildings2024-08-3108208059core:PlantMachinery2024-08-3108208059core:Vehicles2024-08-3108208059core:FurnitureFittings2024-08-3108208059core:OfficeEquipment2024-08-3108208059core:NetGoodwill2024-08-3108208059core:IntangibleAssetsOtherThanGoodwill2024-08-3108208059core:ListedExchangeTraded2024-08-3108208059core:UnlistedNon-exchangeTraded2024-08-3108208059core:LandBuildings2023-08-3108208059core:PlantMachinery2023-08-3108208059core:Vehicles2023-08-3108208059core:FurnitureFittings2023-08-3108208059core:OfficeEquipment2023-08-3108208059core:NetGoodwill2023-08-3108208059core:IntangibleAssetsOtherThanGoodwill2023-08-3108208059core:ListedExchangeTraded2023-08-3108208059core:UnlistedNon-exchangeTraded2023-08-3108208059core:LandBuildings2023-09-012024-08-3108208059core:PlantMachinery2023-09-012024-08-3108208059core:Vehicles2023-09-012024-08-3108208059core:FurnitureFittings2023-09-012024-08-3108208059core:OfficeEquipment2023-09-012024-08-3108208059core:NetGoodwill2023-09-012024-08-3108208059core:IntangibleAssetsOtherThanGoodwill2023-09-012024-08-3108208059core:ListedExchangeTraded2023-09-012024-08-3108208059core:UnlistedNon-exchangeTraded2023-09-012024-08-3108208059core:MoreThanFiveYears2023-09-012024-08-3108208059core:Non-currentFinancialInstruments2024-08-3108208059core:Non-currentFinancialInstruments2023-08-3108208059dpl:CostSales2023-09-012024-08-3108208059dpl:DistributionCosts2023-09-012024-08-3108208059core:LandBuildings2023-09-012024-08-3108208059core:PlantMachinery2023-09-012024-08-3108208059core:Vehicles2023-09-012024-08-3108208059core:FurnitureFittings2023-09-012024-08-3108208059core:OfficeEquipment2023-09-012024-08-3108208059dpl:AdministrativeExpenses2023-09-012024-08-3108208059core:NetGoodwill2023-09-012024-08-3108208059core:IntangibleAssetsOtherThanGoodwill2023-09-012024-08-3108208059dpl:GroupUndertakings2023-09-012024-08-3108208059dpl:ParticipatingInterests2023-09-012024-08-3108208059dpl:GroupUndertakingscore:ListedExchangeTraded2023-09-012024-08-3108208059core:ListedExchangeTraded2023-09-012024-08-3108208059dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-09-012024-08-3108208059core:UnlistedNon-exchangeTraded2023-09-012024-08-3108208059dpl:CostSales2022-09-012023-08-3108208059dpl:DistributionCosts2022-09-012023-08-3108208059core:LandBuildings2022-09-012023-08-3108208059core:PlantMachinery2022-09-012023-08-3108208059core:Vehicles2022-09-012023-08-3108208059core:FurnitureFittings2022-09-012023-08-3108208059core:OfficeEquipment2022-09-012023-08-3108208059dpl:AdministrativeExpenses2022-09-012023-08-3108208059core:NetGoodwill2022-09-012023-08-3108208059core:IntangibleAssetsOtherThanGoodwill2022-09-012023-08-3108208059dpl:GroupUndertakings2022-09-012023-08-3108208059dpl:ParticipatingInterests2022-09-012023-08-3108208059dpl:GroupUndertakingscore:ListedExchangeTraded2022-09-012023-08-3108208059core:ListedExchangeTraded2022-09-012023-08-3108208059dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-09-012023-08-3108208059core:UnlistedNon-exchangeTraded2022-09-012023-08-3108208059core:NetGoodwill2024-08-3108208059core:IntangibleAssetsOtherThanGoodwill2024-08-3108208059core:LandBuildings2024-08-3108208059core:PlantMachinery2024-08-3108208059core:Vehicles2024-08-3108208059core:FurnitureFittings2024-08-3108208059core:OfficeEquipment2024-08-3108208059core:AfterOneYear2024-08-3108208059core:WithinOneYear2024-08-3108208059core:ListedExchangeTraded2024-08-3108208059core:UnlistedNon-exchangeTraded2024-08-3108208059core:ShareCapital2024-08-3108208059core:SharePremium2024-08-3108208059core:RevaluationReserve2024-08-3108208059core:OtherReservesSubtotal2024-08-3108208059core:RetainedEarningsAccumulatedLosses2024-08-3108208059core:NetGoodwill2023-08-3108208059core:IntangibleAssetsOtherThanGoodwill2023-08-3108208059core:LandBuildings2023-08-3108208059core:PlantMachinery2023-08-3108208059core:Vehicles2023-08-3108208059core:FurnitureFittings2023-08-3108208059core:OfficeEquipment2023-08-3108208059core:AfterOneYear2023-08-3108208059core:WithinOneYear2023-08-3108208059core:ListedExchangeTraded2023-08-3108208059core:UnlistedNon-exchangeTraded2023-08-3108208059core:ShareCapital2023-08-3108208059core:SharePremium2023-08-3108208059core:RevaluationReserve2023-08-3108208059core:OtherReservesSubtotal2023-08-3108208059core:RetainedEarningsAccumulatedLosses2023-08-3108208059core:NetGoodwill2022-09-0108208059core:IntangibleAssetsOtherThanGoodwill2022-09-0108208059core:LandBuildings2022-09-0108208059core:PlantMachinery2022-09-0108208059core:Vehicles2022-09-0108208059core:FurnitureFittings2022-09-0108208059core:OfficeEquipment2022-09-0108208059core:AfterOneYear2022-09-0108208059core:WithinOneYear2022-09-0108208059core:ListedExchangeTraded2022-09-0108208059core:UnlistedNon-exchangeTraded2022-09-0108208059core:ShareCapital2022-09-0108208059core:SharePremium2022-09-0108208059core:RevaluationReserve2022-09-0108208059core:OtherReservesSubtotal2022-09-0108208059core:RetainedEarningsAccumulatedLosses2022-09-0108208059core:AfterOneYear2023-09-012024-08-3108208059core:WithinOneYear2023-09-012024-08-3108208059core:Non-currentFinancialInstrumentscore:CostValuation2023-09-012024-08-3108208059core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-09-012024-08-3108208059core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-09-012024-08-3108208059core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-09-012024-08-3108208059core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-09-012024-08-3108208059core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-09-012024-08-3108208059core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-09-012024-08-3108208059core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-09-012024-08-3108208059core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-09-012024-08-3108208059core:Non-currentFinancialInstrumentscore:CostValuation2024-08-3108208059core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-08-3108208059core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-08-3108208059core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-08-3108208059core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-08-3108208059core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-08-3108208059core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-08-3108208059core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-08-3108208059core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-08-3108208059core:Non-currentFinancialInstrumentscore:CostValuation2023-08-3108208059core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-08-3108208059core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-08-3108208059core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-08-3108208059core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-08-3108208059core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-08-3108208059core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-08-3108208059core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-08-3108208059core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-08-3108208059bus:Director12023-09-012024-08-31

PHARMHE (UK) LTD

Registered Number
08208059
(England and Wales)

Unaudited Financial Statements for the Year ended
31 August 2024

PHARMHE (UK) LTD
Company Information
for the year from 1 September 2023 to 31 August 2024

Director

HE, Liang, Dr

Registered Address

Unit 3 Zephyr House
Calleva Park
Aldermaston
RG7 8JN

Registered Number

08208059 (England and Wales)
PHARMHE (UK) LTD
Balance Sheet as at
31 August 2024

Notes

2024

2023

£

£

£

£

Fixed assets
Tangible assets359,0892,781
59,0892,781
Current assets
Stocks792,453704,243
Debtors383,045163,540
Cash at bank and on hand708,727837,461
1,884,2251,705,244
Creditors amounts falling due within one year(1,634,085)(1,361,199)
Net current assets (liabilities)250,140344,045
Total assets less current liabilities309,229346,826
Creditors amounts falling due after one year(155,385)(182,466)
Net assets153,844164,360
Capital and reserves
Called up share capital1,0011,001
Profit and loss account152,843163,359
Shareholders' funds153,844164,360
The financial statements were approved and authorised for issue by the Director on 27 May 2025, and are signed on its behalf by:
HE, Liang, Dr
Director
Registered Company No. 08208059
PHARMHE (UK) LTD
Notes to the Financial Statements
for the year ended 31 August 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
Revenue from sale of goods
Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Employee benefits
Contributions to defined contribution plans are expensed in the period to which they relate.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Tangible fixed assets and depreciation
Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:

Straight line (years)
Vehicles8
Office Equipment3
Stocks and work in progress
Inventories are valued at the lower of cost and estimated selling price (less any associated costs to enable such sales to complete).
2.Average number of employees

20242023
Average number of employees during the year55
3.Tangible fixed assets

Total

£
Cost or valuation
At 01 September 237,646
Additions66,212
At 31 August 2473,858
Depreciation and impairment
At 01 September 234,865
Charge for year9,904
At 31 August 2414,769
Net book value
At 31 August 2459,089
At 31 August 232,781
4.Related party transactions
The company was under the control of Dr. Liang He throughout the current year. Dr. He is the managing director and majority shareholder. Transactions with director arose mainly business expenses paid on behalf of the company. No transactions with related parties were undertaken such as are required to be disclosed under FRS 102 Section 1A.